113 related articles for article (PubMed ID: 14502102)
1. Do effects on blood pressure contribute to improved clinical outcomes with metformin?
Schäfers RF
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S62-70. PubMed ID: 14502102
[TBL] [Abstract][Full Text] [Related]
2. Improving survival with metformin: the evidence base today.
Scarpello JH
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S36-43. PubMed ID: 14502099
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
5. Metformin monotherapy for type 2 diabetes mellitus.
Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
[TBL] [Abstract][Full Text] [Related]
6. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Bailey CJ
Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
[TBL] [Abstract][Full Text] [Related]
7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
8. [New clinical data with metformin therapy in patients with diabetes mellitus].
Jermendy G
Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
10. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
Palumbo PJ
J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of metformin on haemostasis and vascular function in man.
Grant PJ
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
[TBL] [Abstract][Full Text] [Related]
12. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Satoh J
Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.
Uehara MH; Kohlmann NE; Zanella MT; Ferreira SR
Diabetes Obes Metab; 2001 Oct; 3(5):319-25. PubMed ID: 11703421
[TBL] [Abstract][Full Text] [Related]
14. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
[TBL] [Abstract][Full Text] [Related]
15. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
16. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Wolffenbuttel BH; van Haeften TW
Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
[TBL] [Abstract][Full Text] [Related]
17. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E
Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083
[TBL] [Abstract][Full Text] [Related]
18. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Hermann LS; Ranstam J; Vaaler S; Melander A
Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
[TBL] [Abstract][Full Text] [Related]
19. Improved endothelial function with metformin in type 2 diabetes mellitus.
Mather KJ; Verma S; Anderson TJ
J Am Coll Cardiol; 2001 Apr; 37(5):1344-50. PubMed ID: 11300445
[TBL] [Abstract][Full Text] [Related]
20. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
